Inhibrx, Inc.
NASDAQ:INBX
14.6 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Inhibrx, Inc. |
Symbool | INBX |
Munteenheid | USD |
Prijs | 14.6 |
Beurswaarde | 211,348,198 |
Dividendpercentage | 0% |
52-weken bereik | 10.8 - 18.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mark Paul Lappe |
Website | https://inhibrx.com |
An error occurred while fetching data.
Over Inhibrx, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)